8-K/AEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K/A Report, Financial Results (Feb 1, 2011)

Filed February 1, 2011For Securities:BIIB

Summary

This Form 8-K/A filing from Biogen Idec Inc. (BIIB) on February 1, 2011, serves as an amendment to a previous filing, primarily to correct an error in their financial guidance. The company revised its press release regarding the results of operations and financial condition for the full year and three months ended December 31, 2010. The key correction pertains to the 2011 tax rate guidance, which was mistakenly reported as a percentage of total revenue in the initial release. The corrected guidance now states the tax rate will be 26% to 28% of pre-tax income. Investors should note that this amendment focuses solely on this specific financial guidance correction and does not introduce new operational or strategic information beyond what was in the original earnings release, except for the updated tax rate guidance.

Key Highlights

  • 1Biogen Idec filed an 8-K/A on February 1, 2011, to amend a prior filing.
  • 2The amendment corrects the company's press release on full-year and Q4 2010 financial results.
  • 3The primary correction relates to the 2011 tax rate guidance.
  • 4The 2011 tax rate guidance has been revised to be 26% to 28% of pre-tax income.
  • 5The previous press release incorrectly stated the tax rate as a percentage of total revenue.
  • 6The filing includes a revised press release as Exhibit 99.

Frequently Asked Questions

The main purpose of this 8-K/A filing is to amend a previous report and correct an error in Biogen Idec's press release regarding its 2010 financial results and 2011 guidance. Specifically, it corrects the stated tax rate for 2011.

The correction pertains to the 2011 tax rate guidance. The initial press release incorrectly stated it as a percentage of total revenue. The corrected guidance, as provided in this filing, specifies the tax rate will be 26% to 28% of pre-tax income.

No, this filing is an amendment to correct a specific piece of financial guidance (the tax rate). It does not introduce new operational results, strategic initiatives, or other significant business updates beyond the correction of the tax rate guidance previously issued.

Investors should use the corrected tax rate guidance (26%-28% of pre-tax income) for any financial modeling or analysis related to Biogen Idec's expected profitability in 2011. This more accurate guidance is crucial for understanding the company's net income expectations.